PharmaEngine, Inc. (TWO: 4162) announced today that PharmaEngine and Sentinel Oncology Limited have entered into an exclusive license agreement under the option based on a Collaboration and License Agreement on November 26, 2020. PharmaEngine has obtained exclusive rights to develop and commercialize PEP07 worldwide for the treatment of liquid and solid tumors.
Under the Agreement, Sentinel Oncology will be eligible to receive up to $140.5 million upon upfront payment and achievement of certain development, regulatory and sales milestones, as well as tiered royalties on net product sales of PEP07 worldwide.
“We are thrilled to collaborate with Sentinel Oncology to advance the development of this product through global development and commercialization.” Hong-Ren Wang, Ph.D., President and CEO of PharmaEngine, “We are attracted by the promising preclinical data and developability of PEP07 demonstrated during the collaboration. We believe that we could move PEP07 into clinical stage soon and expand the portfolio in the DDR area by identifying new therapeutic targets, based on our successful experience with Onivyde®.”
About PEP07 (aka. SOL-578)
PEP07 is considered a best-in-class checkpoint kinase 1 (CHK1) inhibitor featuring high kinase selectivity, brain penetrating and oral bioavailability which targets the DNA Damage Response (DDR) network. CHK1 inhibitors potentiate the DNA-damaging effects of cytotoxic therapies and/or promote elevated levels of replication stress, leading to tumor cell death. PEP07 has demonstrated significant single-agent activity and combination potential with standard treatments in preclinical cancer models. PEP07 could be used as a monotherapy, or additive and synergistic with other chemotherapy, targeted drugs, or radiotherapy, in hematological and solid tumors.
About PharmaEngine (TWO: 4162)
PharmaEngine, Inc. is a commercial stage oncology company headquartered in Taipei, focusing on the development of new medications for the treatment of cancer. PharmaEngine, Inc. has projects ongoing: ONIVYDE® (Irinotecan Liposome Injection), a commercial drug product which receives marketing authorizations more than 40 countries worldwide, including Taiwan, US, EU, Australia, Canada, Japan, South Korea, Singapore, and China, for the treatment of metastatic pancreatic cancer patients who have progressed on gemcitabine; PEP07, a CHK1 inhibitor which is under development at pre-clinical stage. For further information, please visit PharmaEngine’s website at https://www.pharmaengine.com.
About Sentinel Oncology Limited
Sentinel Oncology was founded in 2005 in Cambridge, UK and is a fully integrated drug discovery company developing and commercializing high quality drug candidates for whom there is currently an unmet medical need. Our pipeline is focused on the design and optimisation of new drugs which can be used to treat primary brain tumors or systemic tumors which frequently metastasise to the brain. Find out more by visiting Sentinel Oncology’s website at https://www.sentineloncology.com.